Hepatocellular carcinoma (HCC) is a heterogeneous tumor–liver–host disease in which treatment selection depends on tumor burden, liver function, portal hypertension, performance status, and patient preferences. Although hepatic resection and other established treatment modalities remain central to curative and disease-...
Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru et al.· Frontiers in Oncology· 0 citations
The historical development and conceptual relationships among EBM, patient safety, QI, LHS, and VBHC are examined, and an integrated framework for understanding their complementary roles in healthcare quality is proposed.
Takehiro Okabayashi, R. Inada, T. Imai et al.· Journal of Evaluation In Cli...· 0 citations
Targeting metabolic pathways represents a promising strategy to enhance liver regeneration and integrating metabolic biomarkers and personalized interventions may improve perioperative outcomes in HCC patients undergoing hepatectomy.
Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru et al.· Nutrition and Cancer· 0 citations
A Dynamic Precision Oncology (DPO) framework is proposed that extends conventional precision oncology beyond baseline molecular profiling by integrating longitudinal assessment of tumor genomics, circulating tumor DNA, CA19-9, imaging, radiomics, and clinical characteristics and summarizes emerging strategies for overc...
